Skip to main content

Lartruvo FDA Approval History

Last updated by Judith Stewart, BPharm on May 4, 2021.

FDA Approved: Yes (Discontinued) (First approved October 19, 2016)
Brand name: Lartruvo
Generic name: olaratumab
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Soft Tissue Sarcoma

Lartruvo (olaratumab) is a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody indicated in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma (STS).

Development timeline for Lartruvo

DateArticle
Apr 25, 2019Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market
Oct 19, 2016Approval FDA Grants Accelerated Approval to Lartruvo (olaratumab) for Advanced Soft Tissue Sarcoma
May  4, 2016FDA Grants Priority Review For Lilly's Olaratumab, An Investigational Medicine For Advanced Soft Tissue Sarcoma

See also

Lartruvo (olaratumab) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer